Pluri Disclosed Signing An Agreement Assigning The Joint Patent Rights To BIRAD–Research & Development Company For Development Of Its PLX Cells For The Treatment Of Cocaine Addiction
Portfolio Pulse from Benzinga Newsdesk
Pluri has signed an agreement with BIRAD–Research & Development Company for the development of its PLX cells to treat cocaine addiction. The deal involves assigning joint patent rights to BIRAD, which could potentially lead to advancements in addiction therapy and provide a new application for Pluri's cell technology.
December 21, 2023 | 12:17 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Pluri's agreement with BIRAD for the development of PLX cells for cocaine addiction treatment could enhance the company's product pipeline and potentially increase its market value if the therapy proves successful.
The agreement with BIRAD is directly related to Pluri's core business of cell therapy development. The assignment of joint patent rights suggests a significant commitment to advancing PLX cells for cocaine addiction treatment. If successful, this could lead to increased investor interest and a higher stock price in the short term. However, the actual impact will depend on the progress and results of the development efforts.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 90